Drugs / Etentamig
Etentamig
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06896916 | Aug 2025 → Mar 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06223516 | Jun 2024 → Feb 2027 expected | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05650632 | Mar 2023 → Aug 2029 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05286229 | Mar 2022 → Mar 2026 overdue | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07600151 | Dec 2026 → Sep 2036 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07420959 | Sep 2026 → Sep 2036 expected | Waldenstrom macroglobulinemia | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06953960 | Jul 2025 → Dec 2030 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06158854 | Apr 2024 → Feb 2028 expected | AL amyloidosis | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03933735 | Jun 2019 → May 2026 overdue | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07095452 | Jan 2026 → Sep 2040 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04453397 | — | plasma cell myeloma | TeneoOne Inc. | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-17 | AbbVie | Results AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting abbvie.com ↗
Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM). |
| 2026-09-03 | AbbVie | Results AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma abbvie.com ↗
The study met its dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS). |
| 2025-12-02 | AbbVie | Results AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers abbvie.com ↗
Preliminary data from the dose escalation portion of the study (n=82) highlight that etentamig in combination with POM+DEX achieved an ORR of 81% and a very good partial response or better (≥VGPR) of 72% at median follow-up of 23 months (range: 1-33 months). |
All press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etentamig | “ABBV-383 (Etentamig)” NCT06158854 ↗ |
| Known as | ABBV-383 | “Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM).” NCT05650632 ↗4“Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM.” NCT05286229 ↗ “Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM.” NCT06223516 ↗ “Etentamig (ABBV-383) as an Intravenous (IV) Infusion” NCT06892522 ↗ |
| Known as | Anti-bcma x acd3 t-bsab tnb-383b | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314973 ↗ |
| Known as | TNB-383B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04453397 ↗ |
| Modality | Monoclonal antibody | “bispecific antibody” NCT04453397 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT05259839 ↗ |